Global Benign Prostatic Hyperplasia (BPH) Drugs Market Research Report 2012-2023

1 Market Overview

1.1 Objectives of Research

1.1.1 Definition

1.1.2 Specifications

1.2 Market Segment

1.2.1 by Type

1.2.1.1 Alpha-blocker

1.2.1.2 Phosphodiesterase Type-5 Inhibitors

1.2.1.3 5-alpha-Reductase Inhibitors

1.2.2 by Application

1.2.2.1 Hospitals

1.2.2.2 Clinics

1.2.2.3 Others

1.2.3 by Regions

2 Industry Chain

2.1 Industry Chain Structure

2.2 Upstream

2.3 Market

2.3.1 SWOT

2.3.2 Dynamics

3 Environmental Analysis

3.1 Policy

3.2 Economic

3.3 Technology

3.4 Market Entry

4 Market Segmentation by Type

4.1 Market Size

4.1.1 Alpha-blocker Market, 2012-2017

4.1.2 Phosphodiesterase Type-5 Inhibitors Market, 2012-2017

4.1.3 5-alpha-Reductase Inhibitors Market, 2012-2017

4.2 Market Forecast

4.2.1 Alpha-blocker Market Forecast, 2018-2023

4.2.2 Phosphodiesterase Type-5 Inhibitors Market Forecast, 2018-2023

4.2.3 5-alpha-Reductase Inhibitors Market Forecast, 2018-2023

5 Market Segmentation by Application

5.1 Market Size

5.1.1 Hospitals Market, 2012-2017

5.1.2 Clinics Market, 2012-2017

5.1.3 Others Market, 2012-2017

5.2 Market Forecast

5.2.1 Hospitals Market Forecast, 2018-2023

5.2.2 Clinics Market Forecast, 2018-2023

5.2.3 Others Market Forecast, 2018-2023

6 Market Segmentation by Region

6.1 Market Size

6.1.1 Asia-Pacific

6.1.1.1 Asia-Pacific Market, 2012-2017

6.1.1.2 Asia-Pacific Market by Type

6.1.1.3 Asia-Pacific Market by Application

6.1.2 North America

6.1.2.1 North America Market, 2012-2017

6.1.2.2 North America Market by Type

6.1.2.3 North America Market by Application

6.1.3 Europe

6.1.3.1 Europe Market, 2012-2017

6.1.3.2 Europe Market by Type

6.1.3.3 Europe Market by Application

6.1.4 South America

6.1.4.1 South America Market, 2012-2017

6.1.4.2 South America Market by Type

6.1.4.3 South America Market by Application

6.1.5 Middle East & Africa

6.1.5.1 Middle East & Africa Market, 2012-2017

6.1.5.2 Middle East & Africa Market by Type

6.1.5.3 Middle East & Africa Market by Application

6.2 Market Forecast

6.2.1 Asia-Pacific Market Forecast, 2018-2023

6.2.2 North America Market Forecast, 2018-2023

6.2.3 Europe Market Forecast, 2018-2023

6.2.4 South America Market Forecast, 2018-2023

6.2.5 Middle East & Africa Market Forecast, 2018-2023

7 Market Competitive

7.1 Global Market by Vendors

7.2 Market Concentration

7.3 Price & Factors

7.4 Marketing Channel

8 Major Vendors

8.1 Astellas Pharma

8.1.2 Profile

8.1.2 Business Performance (Sales Revenue, Cost, Gross Margin)

8.2 Eli Lilly

8.2.1 Profile

8.2.2 Business Performance (Sales Revenue, Cost, Gross Margin)

8.3 GlaxoSmithKline

8.3.1 Profile

8.3.2 Business Performance (Sales Revenue, Cost, Gross Margin)

8.4 Sanofi

8.4.1 Profile

8.4.2 Business Performance (Sales Revenue, Cost, Gross Margin)

8.5 ADC Therapeutics

8.5.1 Profile

8.5.2 Business Performance (Sales Revenue, Cost, Gross Margin)

8.6 Bayer HealthCare

8.6.1 Profile

8.6.2 Business Performance (Sales Revenue, Cost, Gross Margin)

8.7 Bristol-Myers Squibb

8.7.1 Profile

8.7.2 Business Performance (Sales Revenue, Cost, Gross Margin)

8.8 Valeant Pharmaceuticals

8.8.1 Profile

8.8.2 Business Performance (Sales Revenue, Cost, Gross Margin)

8.9 Endo Pharmaceuticals

8.9.1 Profile

8.9.2 Business Performance (Sales Revenue, Cost, Gross Margin)

8.10 Foresee Pharmaceuticals

8.10.1 Profile

8.10.2 Business Performance (Sales Revenue, Cost, Gross Margin)

8.11 Madrigal Pharmaceuticals

8.12 Merck

8.13 Novartis

8.14 Spectrum Pharmaceuticals

8.15 Takeda Pharmaceuticals

8.16 Teva

8.17 Advaxis

8.18 ANI Pharmaceuticals

8.19 BHR Pharma

9 Conclusion

Table Products Segment of Benign Prostatic Hyperplasia (BPH) Drugs

Table Alpha-blocker Overview

Table Phosphodiesterase Type-5 Inhibitors Overview

Table 5-alpha-Reductase Inhibitors Overview

Table Global Benign Prostatic Hyperplasia (BPH) Drugs Market by Type, 2011-2022 (USD Million)

Table Application Segment of Benign Prostatic Hyperplasia (BPH) Drugs

Table Hospitals Overview

Table Clinics Overview

Table Others Overview

Table Global Benign Prostatic Hyperplasia (BPH) Drugs Market by Application, 2011-2022 (USD Million)

Table Global Benign Prostatic Hyperplasia (BPH) Drugs Market by Region, 2011-2022 (USD Million)

Table Cost of Benign Prostatic Hyperplasia (BPH) Drugs

Table Market Dynamics

Table Policy of Benign Prostatic Hyperplasia (BPH) Drugs

Table GDP of Major Countries

Table Alpha-blocker CAGR by Revenue and Volume, 2012-2017

Table Phosphodiesterase Type-5 Inhibitors CAGR by Revenue and Volume, 2012-2017

Table 5-alpha-Reductase Inhibitors CAGR by Revenue and Volume, 2012-2017

Table Alpha-blocker CAGR by Revenue and Volume, 2012-2022

Table Phosphodiesterase Type-5 Inhibitors CAGR by Revenue and Volume, 2012-2022

Table 5-alpha-Reductase Inhibitors CAGR by Revenue and Volume, 2012-2022

Table Hospitals CAGR by Revenue and Volume, 2012-2017

Table Clinics CAGR by Revenue and Volume, 2012-2017

Table Others CAGR by Revenue and Volume, 2012-2017